Debt investors
GSK’s Treasury department monitors and manages the Group’s external and internal funding requirements and financial risks in support of our strategic objectives. GSK operates on a global basis, primarily through subsidiary companies, and we manage our capital to ensure that our subsidiaries are able to operate as going concerns and to optimise returns to shareholders through an appropriate balance of debt and equity.
GSK plc has solicited credit ratings from S&P and Moody’s:
| S&P | Moody's | |
|---|---|---|
| Short-term rating | A-1 | P-1 |
| Long-term rating | A | A2 |
| Outlook | Stable | Negative |
As at 31st March 2021
GSK’s policy is to borrow centrally in order to meet anticipated funding requirements. The strategy is to diversify liquidity sources using a range of facilities and to maintain broad access to financial markets.
Short-term liquidity
GSK has access to short-term finance under a $10 billion US commercial paper programme; £5 billion Euro commercial paper programme; £1.9 billion of medium-term committed facilities; $2.5 billion of 364 day committed facilities as well as the use of cash and cash equivalents and liquid investments.
The committed facilities were undrawn as at 31st March 2021.
Medium / long-term liquidity
GSK has a £20 billion Euro Medium Term Note (EMTN) programme and a US shelf registration.
|
Programme |
Limit |
Rating (S&P/Moody’s) |
|
US Commercial Paper Euro Commercial Paper |
$10 billion £5 billion |
A-1 / P-1 A-1 / P-1 |
|
Euro Medium Term Note programme |
£20 billion |
A / A2 |
|
US Shelf |
Unlimited |
A / A2 |
Issuing entities listed under EMTN programme:
- GlaxoSmithKline plc
- GlaxoSmithKline Capital plc
- GSK Capital K.K.
Issuing entities listed under US shelf programme:
- GlaxoSmithKline plc
- GlaxoSmithKline Capital plc
- GlaxoSmithKline Capital Inc.
Below is a table of the bonds guaranteed by GSK plc as at 31st March 2021
|
Issuer |
Issue currency |
Issue amount (millions) |
Issue date |
Maturity date |
Programme |
Coupon |
ISIN |
|
Capital plc |
USD |
750 |
15/05/2018 |
14/05/2021 |
US Shelf |
LIBOR + 0.350% |
US377373AF20 |
|
Capital plc |
EUR |
1500 |
23/09/2019 |
23/09/2021 |
EMTN |
EURIBOR + 0.600%_ |
XS2054626358 |
|
Capital plc |
EUR |
500 |
23/09/2019 |
23/09/2021 |
EMTN |
0.000% |
XS2054626515 |
|
Capital plc |
USD |
2,000 |
09/05/2012 |
08/05/2022 |
US Shelf |
2.850% |
US377373AD71 |
|
Capital plc |
USD |
1,500 |
25/03/2019 |
01/06/2022 |
US Shelf |
2.875% |
US377373AJ42 |
|
Capital Inc |
USD |
1,250 |
18/03/2013 |
18/03/2023 |
US Shelf |
2.800% |
US377372AH03 |
|
Capital plc |
EUR |
750 |
12/05/2020 |
12/05/2023 |
EMTN |
0.125% |
XS2170609403 |
|
Capital Inc |
USD |
1,250 |
15/05/2018 |
15/05/2023 |
US Shelf |
3.375% |
US377372AL15 |
|
Finance (No.3) plc |
USD |
280 |
22/06/2020 |
22/06/2023 |
Exchangeable |
0.000% |
US36259RAA05 |
|
Capital plc |
EUR |
500 |
23/09/2019 |
23/09/2023 |
EMTN |
0.000% |
XS2054626788 |
|
Capital plc |
USD |
1,250 |
01/10/2020 |
01/10/2023 |
US Shelf |
0.534% |
US377373AL97 |
|
Capital plc |
USD |
1,000 |
25/03/2019 |
01/06/2024 |
US Shelf |
3.000% |
US377373AG03 |
|
Capital plc |
EUR |
1,000 |
02/12/2014 |
02/12/2024 |
EMTN |
1.375% |
XS1147605791 |
|
Capital Inc |
USD |
1,000 |
15/05/2018 |
15/05/2025 |
US Shelf |
3.625% |
US377372AM97 |
|
Capital plc |
EUR |
750 |
16/06/2005 |
16/06/2025 |
EMTN |
4.000% |
XS0222383027 |
|
Capital plc |
EUR |
1,000 |
21/05/2018 |
21/05/2026 |
EMTN |
1.250% |
XS1822828122 |
|
Capital plc |
EUR |
700 |
12/09/2017 |
12/09/2026 |
EMTN |
1.000% |
XS1681519184 |
|
Capital plc |
GBP |
600 |
18/12/2012 |
20/12/2027 |
EMTN |
3.375% |
XS0866588527 |
|
Capital Inc |
USD |
1,750 |
15/05/2018 |
15/05/2028 |
US Shelf |
3.875% |
US377372AN70 |
|
Capital plc |
GBP |
750 |
12/05/2020 |
12/10/2028 |
EMTN |
1.250% |
XS2170601848 |
|
Capital plc |
USD |
1,000 |
25/03/2019 |
01/06/2029 |
US Shelf |
3.375% |
US377373AH85 |
|
Capital plc |
EUR |
500 |
12/09/2017 |
12/09/2029 |
EMTN |
1.375% |
XS1681520356 |
|
Capital plc |
EUR |
750 |
21/05/2018 |
21/05/2030 |
EMTN |
1.750% |
XS1822829799 |
|
Capital plc |
GBP |
1,000 |
19/12/2001 |
19/12/2033 |
EMTN |
5.250% |
XS0140516864 |
|
Capital Inc |
USD |
500 |
06/04/2004 |
15/04/2034 |
US Shelf |
5.375% |
US377372AB33 |
|
Capital plc |
GBP |
750 |
12/05/2020 |
12/05/2035 |
EMTN |
1.625% |
XS2170609072 |
|
Capital Inc |
USD |
2,750 |
13/05/2008 |
15/05/2038 |
US Shelf |
6.375% |
US377372AE71 |
|
Capital plc |
GBP |
700 |
06/03/2008 |
09/03/2039 |
EMTN |
6.375% |
XS0350820931 |
|
Capital plc |
GBP |
1,000 |
10/04/2007 |
10/04/2042 |
EMTN |
5.250% |
XS0294624373 |
|
Capital Inc |
USD |
500 |
18/03/2013 |
18/03/2043 |
US Shelf |
4.200% |
US377372AJ68 |
|
Capital plc |
GBP |
800 |
18/12/2012 |
18/12/2045 |
EMTN |
4.250% |
XS0866596975 |
Bond debt maturity profile (£bn equivalent)
USD and EUR bonds converted to GBP using the spot rates on 31st March 2021 as follows:
GBPEUR 1.1728
GBPUSD 1.3762
Total gross bond debt in issue as at 31st March 2021: £24.6bn
Timothy Woodthorpe
Senior Vice President and Group Treasurer
Email: cf.treasury@gsk.com
GSK Investor Relations
Email: GSK.Investor-Relations@gsk.com
Tel: +44 (0)20 8047 5000